Wall Street analysts expect Mersana Therapeutics Inc (NASDAQ:MRSN) to post sales of $1.08 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Mersana Therapeutics’ earnings, with the highest sales estimate coming in at $1.25 million and the lowest estimate coming in at $1.00 million. Mersana Therapeutics posted sales of $4.19 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 74.2%. The company is scheduled to announce its next earnings report on Tuesday, August 13th.
According to Zacks, analysts expect that Mersana Therapeutics will report full-year sales of $42.98 million for the current financial year, with estimates ranging from $41.04 million to $44.79 million. For the next financial year, analysts anticipate that the company will report sales of $4.83 million, with estimates ranging from $4.00 million to $5.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.73. The company had revenue of $41.04 million during the quarter, compared to the consensus estimate of $30.11 million. Mersana Therapeutics had a negative return on equity of 57.49% and a negative net margin of 61.68%.
MRSN has been the topic of several research analyst reports. Cowen reaffirmed a “buy” rating on shares of Mersana Therapeutics in a research note on Sunday, June 2nd. Zacks Investment Research cut Mersana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. JPMorgan Chase & Co. cut Mersana Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, March 11th. Finally, Robert W. Baird set a $12.00 target price on Mersana Therapeutics and gave the company a “buy” rating in a research report on Friday, March 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $21.60.
Shares of NASDAQ MRSN traded down $0.09 during mid-day trading on Thursday, reaching $4.10. The company had a trading volume of 114,800 shares, compared to its average volume of 238,246. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.24 and a current ratio of 6.24. Mersana Therapeutics has a one year low of $2.85 and a one year high of $19.60. The firm has a market cap of $199.95 million, a price-to-earnings ratio of -1.47 and a beta of 1.39. The company has a 50-day moving average price of $4.46.
Hedge funds have recently bought and sold shares of the business. NEA Management Company LLC lifted its position in shares of Mersana Therapeutics by 46.0% during the 1st quarter. NEA Management Company LLC now owns 11,894,267 shares of the company’s stock valued at $62,564,000 after buying an additional 3,750,000 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Mersana Therapeutics in the 1st quarter worth $1,052,000. Vanguard Group Inc. increased its holdings in shares of Mersana Therapeutics by 34.4% in the 3rd quarter. Vanguard Group Inc. now owns 601,101 shares of the company’s stock worth $6,011,000 after purchasing an additional 153,923 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Mersana Therapeutics in the 4th quarter worth $277,000. Finally, Bank of America Corp DE increased its holdings in shares of Mersana Therapeutics by 1,409.6% in the 4th quarter. Bank of America Corp DE now owns 31,807 shares of the company’s stock worth $129,000 after purchasing an additional 29,700 shares in the last quarter. 77.40% of the stock is currently owned by institutional investors and hedge funds.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Featured Article: The limitations of an equal weight rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.